TABLE 3.

Unadjusted and Adjusted Hazard Ratios for All-Cause Mortality and Specific Clinical Events by Baseline Smoking Status: Strategies for Management of Antiretroviral Therapy Clinical Trial, 2002–2006

	Current Versus Never Smokers		Current Versus Former Smokers
Clinical Event	HR (95% CI)	P	HR (95% CI)	P
All-cause mortality
Unadjusted	3.0 (1.9, 4.7)	<.001	1.3 (0.9, 1.8)	.15
Adjusted	2.4 (1.5, 3.8)	<.001	1.5 (1.0, 2.1)	.04
AIDS-related disease
Unadjusted	1.6 (1.1, 2.3)	.01	1.6 (1.1, 2.4)	.02
Adjusted	1.3 (0.9, 1.9)	.18	1.6 (1.0, 2.3)	.03
Major CVD
Unadjusted	1.8 (1.2, 2.8)	.004	1.2 (0.8, 1.8)	.31
Adjusted	2.0 (1.3, 3.1)	.002	1.6 (1.1, 2.4)	.02
Expanded CVDa
Unadjusted	1.9 (1.3, 2.6)	<.001	1.2 (0.9, 1.6)	.25
Adjusted	1.9 (1.4, 2.7)	<.001	1.5 (1.1, 2.1)	.009
Non-AIDS cancer
Unadjusted	1.7 (1.1, 2.5)	.01	1.6 (1.0, 2.5)	.03
Adjusted	1.8 (1.2, 2.8)	.008	2.3 (1.5, 3.6)	<.001
Major Renal disease
Unadjusted	6.6 (0.8, 52.4)	.08	0.6 (0.2, 1.5)	.24
Adjusted	6.6 (0.8, 53.9)	.08	0.7 (0.2, 1.7)	.4
Major Hepatic disease
Unadjusted	1.9 (0.7, 5.5)	.22	0.9 (0.4, 2.3)	.91
Adjusted	0.6 (0.2, 1.8)	.32	0.8 (0.3, 2.1)	.69
Bacterial pneumoniab
Unadjusted	2.5 (1.7, 3.6)	<.001	1.5 (1.0, 2.0)	.03
Adjusted	2.3 (1.6, 3.3)	<.001	1.5 (1.1, 2.1)	.01

Note. CI = confidence interval; CVD = cardiovascular disease; HR = hazard ratio. All models adjusted for treatment group, age, gender, race/ethnicity (Black, Hispanic, other), baseline HIV RNA, and baseline and nadir CD4+ counts. Death and AIDS endpoints additionally adjusted for alcohol abuse, injection drug use, and previous AIDS disease. CVD endpoints additionally adjusted for body mass index, diabetes, blood pressure–lowering drugs, lipid-lowering drugs, low-density lipoprotein cholesterol, and triglycerides. Cancer and liver endpoints additionally adjusted for alcohol abuse, injection drug use, and hepatitis B or C.

^aMajor CVD events, as well as congestive heart failure, coronary artery disease requiring drug treatment, or peripheral vascular disease.

^bInitial occurrence.